Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab + Docetaxel in NSCLC
NCT02358473Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mogamulizumab in non-small cell lung cancer (NSCLC), sponsored by Kyowa Kirin. Primary endpoints: Number of Subjects Reporting Adverse Events, Number of Subjects Reporting Serious Adverse Events and 1 more. Started Jan 2015; status: completed.
02
Drugs
mogamulizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02358473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358473.